Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis

Medical Oncology

Volumn 31, Issue 3, 2014, Pages

  Lekovic, Danijela ^a   Gotic, Mirjana ^a,b   Perunicic Jovanovic, Maja ^a   Vidovic, Ana ^a,b   Bogdanovic, Andrija ^a,b   Jankovic, Gradimir ^a,b   Cokic, Vladan ^b   Milic, Natasa ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Comorbidity score; Grade of bone marrow fibrosis; International Prognostic Scoring System; Primary myelofibrosis; Prognosis

Indexed keywords

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; COMORBIDITY; DISEASE SEVERITY; FEMALE; HEMATOPOIETIC CELL; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LABORATORY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL; VERY ELDERLY; BONE MARROW DISEASE; CANCER GRADING; FIBROSIS; FOLLOW UP; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SERBIA; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW DISEASES; COMORBIDITY; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PRIMARY MYELOFIBROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SERBIA; SURVIVAL RATE;

EID: 84893190328     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0869-8     Document Type: Article

References (28)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
2. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520-30.
3. Kralovic R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
4. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-38.
5. Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, et al. Identification of "long-lived" and "short-lived" patients at presentation of primary myelofibrosis. Br J Haematol. 1997;97(3):635-40.
6. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905-14.
7. Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109(10):2083-8.
8. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013-8.
9. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102(3):684-90.
10. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-93.
11. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113(13):2895-901.
12. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007;13(6):377-83.
13. Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355-65.
14. Verstovsek S. JAK2 inhibitors and myeloproliferative neoplasms. Clin Adv Hematol Oncol. 2008;6(12):878-80 896.
15. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-32.
16. Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D. The measurement of comorbidity by cancer registries. J Registry Manag. 2003;30:8-14.
17. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9.
18. Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph (1+) chronic myelogenous leukaemia: a multicenter trial. J Clin Oncol. 2001;19(12):2994-3009.
19. Subramanian R, Basu D, Dutta TK. Significance of bone marrow fibrosis in multiple myeloma. Pathology. 2007;39(5):512-5.
20. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-62.
21. Vener C, Fracchiolla NS, Gianelli U, Calori R, Radaelli F, Iurlo A, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111(4):1862-5.
22. Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol. 2012;25(9):1193-202.
23. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings - a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol. 2006;85(4):226-32.
24. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-7.
25. Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29(16):2240-6.
26. Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res. 2009;33(12):1594-8.
27. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874-83.
28. Kieszak SM, Flanders WD, Kosinski AS, Shipp CC, Karp H. A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol. 1999;52(2):137-42.